{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T20:53:23Z","timestamp":1786136003728,"version":"build-2736575974"},"reference-count":43,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"32","license":[{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,7]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>This study compares the safety signals of 3 glycoprotein IIb\/IIIa inhibitors (GPIs) \u2013 tirofiban, abciximab, and eptifibatide \u2013 using the US Food and Drug Administration Adverse Event Reporting System, aiming to guide clinical application. We extracted reports listing the 3 GPIs as the primary suspect from the US Food and Drug Administration Adverse Event Reporting System database. Adverse events were systematically coded using preferred terms and subsequently mapped to system organ classes. To identify potential safety signals, we employed disproportionality analysis algorithms, including the proportional reporting ratio and reporting odds ratio, with predefined thresholds for signal detection. A total of 4911 reports were analyzed (tirofiban: 2352; abciximab: 1295; and eptifibatide: 1264). At the system organ classes level, all 3 GPIs showed positive signals for cardiac disorders, vascular disorders, blood and lymphatic system disorders, and respiratory, thoracic, and mediastinal disorders. Tirofiban demonstrated the strongest cardiovascular signals, followed by abciximab, whereas eptifibatide showed distinct signals in investigations (e.g., laboratory abnormalities) and gastrointestinal disorders. Tirofiban and abciximab also exhibited signals in various nervous system disorders. At the preferred terms level, thrombocytopenia and multi-site hemorrhage were common to all 3 GPIs, consistent with product labeling information. Distinctive signals emerged: tirofiban signals highlighted intracranial hemorrhage and vascular access site bleeding, plus restenosis and reocclusion. Abciximab showed the broadest mucosal bleeding profile (oral, nasal, pharyngeal, otic, conjunctival, and urinary tract) and Mallory\u2013Weiss syndrome. Eptifibatide signals included retroperitoneal hemorrhage, mediastinal hematoma, and bleeding at tracheal, spinal, pelvic, and joint sites, with notable signals for hemorrhagic pancreatitis and anaphylaxis. All 3 GPIs are strongly associated with hemorrhage and thrombocytopenia but differ in risk patterns. Tirofiban signals emphasize cerebrocardiovascular bleeding risks (intracranial and vascular access sites). Eptifibatide signals indicate broader systemic involvement. Abciximab signals highlight oropharyngeal, otorhinolaryngologic, and urinary tract mucosal surfaces. These findings support pharmacovigilance and warrant validation through prospective studies, with the understanding that all reported associations are based on statistical signals from a spontaneous reporting system and do not establish causality.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000050132","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T18:01:12Z","timestamp":1786125672000},"page":"e50132","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacovigilance analysis of glycoprotein IIb\/IIIa inhibitors: A FAERS-based signal detection study"],"prefix":"10.1097","volume":"105","author":[{"given":"Cheng","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Comprehensive Ward, The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China"},{"name":"The Key Laboratory of Myocardial Remodeling Research, The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junxia","family":"Cao","sequence":"additional","affiliation":[{"name":"Nursing Department, Guizhou Nursing Vocational College, Guiyang, Guizhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China"},{"name":"The Key Laboratory of Myocardial Remodeling Research, The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiling","family":"Xia","sequence":"additional","affiliation":[{"name":"The Cadre Medical Department, Guizhou Provincial People\u2019s Hospital, Guiyang, Guizhou, China"},{"name":"The Key Laboratory of Myocardial Remodeling Research, The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Yan","sequence":"additional","affiliation":[{"name":"The Key Laboratory of Myocardial Remodeling Research, The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Yang","sequence":"additional","affiliation":[{"name":"The Key Laboratory of Myocardial Remodeling Research, The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoxing","family":"Cao","sequence":"additional","affiliation":[{"name":"The Key Laboratory of Myocardial Remodeling Research, The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runze","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China"},{"name":"The Key Laboratory of Myocardial Remodeling Research, The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4666-8412","authenticated-orcid":false,"given":"Zhangrong","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China"},{"name":"The Key Laboratory of Myocardial Remodeling Research, The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260807","doi-asserted-by":"crossref","first-page":"101201","DOI":"10.1016\/j.cpcardiol.2022.101201","article-title":"Improving wellbeing after acute coronary syndrome.","volume":"48","author":"Liblik","year":"2023","journal-title":"Curr Probl Cardiol"},{"key":"R2-20260807","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12950-023-00344-z","article-title":"Neutrophil extracellular traps in acute coronary syndrome.","volume":"20","author":"Wu","year":"2023","journal-title":"J Inflamm (Lond)"},{"key":"R3-20260807","first-page":"502","article-title":"Treatment of acute coronary syndromes.","volume":"149","author":"Hundertmark","year":"2024","journal-title":"Dtsch Med Wochenschr"},{"issue":"2 Suppl 2","key":"R4-20260807","first-page":"e1","article-title":"Linee guida ESC 2023 per il trattamento delle sindromi coronariche acute (2023 ESC Guidelines for the management of acute coronary syndromes).","volume":"25","author":"Byrne","year":"2024","journal-title":"G Ital Cardiol (Rome)"},{"key":"R5-20260807","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/j.jacc.2024.06.013","article-title":"2024 AHA\/ACC\/ACS\/ASNC\/HRS\/SCA\/SCCT\/SCMR\/SVM guideline for perioperative cardiovascular management for noncardiac surgery: a report of the American College of Cardiology\/American Heart association joint committee on clinical practice guidelines.","volume":"84","author":"Thompson","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"R6-20260807","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s12872-022-02563-3","article-title":"Efficacy and safety of a bridging strategy that uses intravenous platelet glycoprotein receptor inhibitors for patients undergoing surgery after coronary stent implantation: a meta-analysis.","volume":"22","author":"Wu","year":"2022","journal-title":"BMC Cardiovasc Disord"},{"key":"R7-20260807","doi-asserted-by":"crossref","first-page":"64","DOI":"10.18087\/cardio.2022.4.n2020","article-title":"The role of platelet glycoprotein IIb \/ IIIa inhibitors in current treatment of acute coronary syndrome.","volume":"62","author":"Sukhinina","year":"2022","journal-title":"Kardiologiia"},{"issue":"Suppl 1","key":"R8-20260807","doi-asserted-by":"crossref","first-page":"P445","DOI":"10.1093\/eurheartj\/eht307.P445","article-title":"GP IIb\/IIIa inhibitors improve outcome in patients with primary PCI for STEMI. Results of the prospective ALKK-registry.","volume":"34","author":"Zeymer","year":"2013","journal-title":"Eur Heart J"},{"key":"R9-20260807","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.3390\/biomedicines12092023","article-title":"Current and future roles of glycoprotein IIb\/IIIa inhibitors in primary angioplasty for ST-segment elevation myocardial infarction.","volume":"12","author":"De Luca","year":"2024","journal-title":"Biomedicines"},{"key":"R10-20260807","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1093\/eurheartj\/ehp118","article-title":"Risk profile and benefits from Gp IIb\/IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials.","volume":"30","author":"De Luca","year":"2009","journal-title":"Eur Heart J"},{"key":"R11-20260807","doi-asserted-by":"crossref","first-page":"9","DOI":"10.11604\/pamj.2021.38.9.27215","article-title":"Thrombocytopenia induced by glycoprotein (GP) IIb\/IIIa antagonists: about two cases.","volume":"38","author":"Abdeladim","year":"2021","journal-title":"Pan Afr Med J"},{"key":"R12-20260807","first-page":"e82117","article-title":"Tirofiban-induced profound thrombocytopenia: a case report.","volume":"17","author":"Al Achkar","year":"2025","journal-title":"Cureus"},{"key":"R13-20260807","doi-asserted-by":"crossref","first-page":"8553","DOI":"10.4076\/1757-1626-2-8553","article-title":"A retrospective analysis and case series of glycoprotein IIb\/IIIa inhibitor associated diffuse alveolar hemorrhage: two case reports.","volume":"2","author":"Mikkilineni","year":"2009","journal-title":"Cases J"},{"key":"R14-20260807","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio.","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R15-20260807","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports.","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R16-20260807","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/pds.885","article-title":"Disproportionality analysis using empirical Bayes data mining: a tool for the evaluation of drug interactions in the post-marketing setting.","volume":"12","author":"Almenoff","year":"2003","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R17-20260807","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation.","volume":"54","author":"Bate","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"R18-20260807","doi-asserted-by":"crossref","first-page":"17070","DOI":"10.1038\/s41598-025-01527-9","article-title":"Safety comparisons among different subcutaneous anticoagulants for venous thromboembolism using FDA adverse event reporting system.","volume":"15","author":"Lu","year":"2025","journal-title":"Sci Rep"},{"key":"R19-20260807","doi-asserted-by":"crossref","first-page":"18641","DOI":"10.1038\/s41598-025-03850-7","article-title":"Comparative analysis of adverse event profiles of lanreotide and octreotide in somatostatin-responsive endocrine and neoplastic diseases.","volume":"15","author":"Wang","year":"2025","journal-title":"Sci Rep"},{"key":"R20-20260807","doi-asserted-by":"crossref","first-page":"1338902","DOI":"10.3389\/fphar.2024.1338902","article-title":"Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database.","volume":"15","author":"Zou","year":"2024","journal-title":"Front Pharmacol"},{"key":"R21-20260807","doi-asserted-by":"crossref","first-page":"1509310","DOI":"10.3389\/fphar.2024.1509310","article-title":"Safety assessment of tolvaptan: real-world adverse event analysis using the FAERS database.","volume":"15","author":"Cao","year":"2024","journal-title":"Front Pharmacol"},{"key":"R22-20260807","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s12916-023-02858-y","article-title":"Statistical analysis of high-dimensional biomedical data: a gentle introduction to analytical goals, common approaches and challenges.","volume":"21","author":"Rahnenf\u00fchrer","year":"2023","journal-title":"BMC Med"},{"key":"R23-20260807","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1056\/NEJMoa0708191","article-title":"Bivalirudin during primary PCI in acute myocardial infarction.","volume":"358","author":"Stone","year":"2008","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"R24-20260807","first-page":"1395","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndrome undergoing complex percutaneous coronary intervention.","volume":"99","author":"Li","year":"2022","journal-title":"Catheter Cardiovasc Interv"},{"key":"R25-20260807","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ahj.2021.04.013","article-title":"Cangrelor vs. glycoprotein IIb\/IIIa inhibitors during percutaneous coronary intervention.","volume":"238","author":"Yerasi","year":"2021","journal-title":"Am Heart J"},{"key":"R26-20260807","first-page":"949","article-title":"Report on cardiovascular health and diseases in China 2023: an updated summary.","volume":"37","year":"2024","journal-title":"Biomed Environ Sci"},{"key":"R27-20260807","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/s11239-012-0713-y","article-title":"Age-related differences in treatment strategies and clinical outcomes in unselected cohort of patients with ST-segment elevation myocardial infarction transferred for primary angioplasty.","volume":"34","author":"Dziewierz","year":"2012","journal-title":"J Thromb Thrombolysis"},{"key":"R28-20260807","doi-asserted-by":"crossref","first-page":"878566","DOI":"10.3389\/fcvm.2022.878566","article-title":"Sex differences in characteristics, treatments, and in-hospital outcomes of patients undergoing coronary angiography or intervention.","volume":"9","author":"Chen","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"R29-20260807","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.3174\/ajnr.A6814","article-title":"Antiplatelet management for stent-assisted coiling and flow diversion of ruptured intracranial aneurysms: a DELPHI consensus statement.","volume":"41","author":"Ospel","year":"2020","journal-title":"AJNR Am J Neuroradiol"},{"issue":"11 Suppl","key":"R30-20260807","first-page":"S57","article-title":"Platelet GPIIb\/IIIa antagonists: the first anti-integrin receptor therapeutics.","volume":"100","author":"Coller","year":"1997","journal-title":"J Clin Invest"},{"key":"R31-20260807","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/j.1540-8191.2001.tb01172.x","article-title":"Emergency coronary artery bypass surgery in the era of glycoprotein IIb\/IIIa receptor antagonist use.","volume":"17","author":"Pang","year":"2002","journal-title":"J Card Surg"},{"key":"R32-20260807","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s43678-025-00915-4","article-title":"Tirofiban for stroke without large- or medium-sized vessel occlusion.","volume":"27","author":"Roberts","year":"2025","journal-title":"CJEM"},{"key":"R33-20260807","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s10238-011-0171-4","article-title":"Tirofiban versus abciximab: tirofiban is administered at suboptimal dosages when evaluated in an arterial thrombosis model in non-human primates.","volume":"12","author":"van Rensburg","year":"2012","journal-title":"Clin Exp Med"},{"key":"R34-20260807","article-title":"Impact of renal dysfunction and acute kidney injury on outcome in elderly patients with acute coronary syndrome undergoing percutaneous coronary intervention.","volume":"10","author":"De Rosa","year":"2021","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"R35-20260807","doi-asserted-by":"crossref","first-page":"297","DOI":"10.4103\/1319-2442.395445","article-title":"Acute kidney injury in acute myocardial infarction and its outcome at 3 and 6 months.","volume":"34","author":"Kaur","year":"2023","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"R36-20260807","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/CRD.0b013e31817a7de9","article-title":"Glycoprotein IIb\/IIIa inhibitors in patients with renal insufficiency undergoing percutaneous coronary intervention.","volume":"16","author":"Anderson","year":"2008","journal-title":"Cardiol Rev"},{"key":"R37-20260807","doi-asserted-by":"crossref","first-page":"1076029620942594","DOI":"10.1177\/1076029620942594","article-title":"Safety of glycoprotein IIb\/IIIa inhibitors used in stroke-related treatment: a systematic review and meta-analysis.","volume":"26","author":"Zhu","year":"2020","journal-title":"Clin Appl Thromb Hemost"},{"key":"R38-20260807","doi-asserted-by":"crossref","first-page":"e031855","DOI":"10.1161\/JAHA.123.031855","article-title":"Critical analysis of thrombocytopenia associated with glycoprotein IIb\/IIIa inhibitors and potential role of zalunfiban, a novel small molecule glycoprotein inhibitor, in understanding the mechanism(s).","volume":"12","author":"Rikken","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"R39-20260807","doi-asserted-by":"crossref","first-page":"2233425","DOI":"10.1080\/07853890.2023.2233425","article-title":"Tirofiban-induced thrombocytopenia.","volume":"55","author":"Wang","year":"2023","journal-title":"Ann Med"},{"key":"R40-20260807","doi-asserted-by":"crossref","first-page":"ytad005","DOI":"10.1093\/ehjcr\/ytad005","article-title":"Probable tirofiban-induced thrombotic microangiopathy after stent thrombosis: a case report.","volume":"7","author":"Mattioli","year":"2023","journal-title":"Eur Heart J Case Rep"},{"key":"R41-20260807","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1212\/WNL.43.5.957","article-title":"The capsular warning syndrome: pathogenesis and clinical features.","volume":"43","author":"Donnan","year":"1993","journal-title":"Neurology"},{"key":"R42-20260807","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/ijs.12432","article-title":"Clinical characteristics and outcome of the capsular warning syndrome: a multicenter study.","volume":"10","author":"Camps-Renom","year":"2015","journal-title":"Int J Stroke"},{"key":"R43-20260807","doi-asserted-by":"crossref","first-page":"1026127","DOI":"10.3389\/fnins.2022.1026127","article-title":"Clinical safety and possible efficacy of tirofiban in combination with intravenous thrombolysis by recombinant tissue plasminogen activator for early treatment of capsular warning syndrome (CWS).","volume":"16","author":"Liu","year":"2022","journal-title":"Front Neurosci"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050132","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T20:02:01Z","timestamp":1786132921000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,7]]},"references-count":43,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000050132","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,7]]},"assertion":[{"value":"2026-01-27","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-24","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}